Guided P2Y12 inhibitor therapy after percutaneous coronary intervention - The Lancet
JCM | Free Full-Text | De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature | HTML
Pre-Procedural Ticagrelor Treatment in Myocardial Infarction | IJGM
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI - ScienceDirect
Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial | Trials | Full Text
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | tctmd.com
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention - American Journal of Cardiology
Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial | Journal of the American Heart Association
2 3 De escalation strategies
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
CABG Ticagrelor versus clopidogrel in patients with acute
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada - CJC Open
Dosing & Administration | BRILINTA® (ticagrelor) tablets | For HCPs
Antiplatelet therapy in coronary artery disease
Overview of Antiplatelet Therapy for Myocardial Infarction | Thoracic Key
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI | JACC: Cardiovascular Interventions
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Trial schema for the IMPRESSION study. Legend: IV: intravenous; PCI:... | Download Scientific Diagram
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
